| Jeffrey K Zawacki, MD | |
|
3245 Grove Ave, Suite 202, Berwyn, IL 60402-3474 | |
| (708) 484-0621 | |
| (708) 484-0250 |
| Full Name | Jeffrey K Zawacki |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 32 Years |
| Location | 3245 Grove Ave, Berwyn, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790774750 | NPI | - | NPPES |
| 036089882 | Medicaid | IL | |
| 01619787 | Other | BCBSIL GROUP NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 036-089882 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Macneal Hospital | Berwyn, IL | Hospital |
| Adventist Hinsdale Hospital | Hinsdale, IL | Hospital |
| Adventist La Grange Memorial Hospital | La grange, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Suburban Surgical Associates Ltd | 0143247056 | 2 |
News Archive
Physicians for a National Health Program suggest the proposal in Vermont falls "far short" of their goals, The Hill Reports. Meanwhile, The Boston Globe has an interview with one of the architects of the Vermont plan.
A gene that regulates bone growth and muscle metabolism in mammals may take on an additional role as a promoter of brain maturation, cognition and learning in human and nonhuman prim ates, according to a new study led by neurobiologists at Harvard Medical School.
Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.
Many of us are aware that we shouldn't eat too much salt. To be precise, adults should avoid eating over 6g (or around about a teaspoon of salt) a day.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 7 days ago
| Entity Name | Suburban Surgical Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821088667 PECOS PAC ID: 0143247056 Enrollment ID: O20051031000385 |
News Archive
Physicians for a National Health Program suggest the proposal in Vermont falls "far short" of their goals, The Hill Reports. Meanwhile, The Boston Globe has an interview with one of the architects of the Vermont plan.
A gene that regulates bone growth and muscle metabolism in mammals may take on an additional role as a promoter of brain maturation, cognition and learning in human and nonhuman prim ates, according to a new study led by neurobiologists at Harvard Medical School.
Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.
Many of us are aware that we shouldn't eat too much salt. To be precise, adults should avoid eating over 6g (or around about a teaspoon of salt) a day.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey K Zawacki, MD 3245 Grove Ave, Suite 202, Berwyn, IL 60402-3474 Ph: (708) 484-0621 | Jeffrey K Zawacki, MD 3245 Grove Ave, Suite 202, Berwyn, IL 60402-3474 Ph: (708) 484-0621 |
News Archive
Physicians for a National Health Program suggest the proposal in Vermont falls "far short" of their goals, The Hill Reports. Meanwhile, The Boston Globe has an interview with one of the architects of the Vermont plan.
A gene that regulates bone growth and muscle metabolism in mammals may take on an additional role as a promoter of brain maturation, cognition and learning in human and nonhuman prim ates, according to a new study led by neurobiologists at Harvard Medical School.
Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.
Many of us are aware that we shouldn't eat too much salt. To be precise, adults should avoid eating over 6g (or around about a teaspoon of salt) a day.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 7 days ago
Dr. Mark S Choh, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3245 Grove Ave, #202, Berwyn, IL 60402 Phone: 708-484-0621 Fax: 708-484-0250 | |
Mary Beth Leonard, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3245 Grove Ave, Berwyn, IL 60402 Phone: 708-484-0621 Fax: 708-484-0250 | |
Mouhammad E Souman, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 3452 Grove Ave, Suite 202, Berwyn, IL 60402 Phone: 708-484-0621 Fax: 708-484-0250 | |
Jayantibhai Gopalbhai Patel, MD Surgery Medicare: Medicare Enrolled Practice Location: 6834 W Cermak Road, Berwyn, IL 60402 Phone: 708-788-6270 Fax: 708-788-6271 | |
Dr. Robin Lynn Favor, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3245 Grove Ave, Suite 202, Berwyn, IL 60402 Phone: 708-484-0621 Fax: 708-484-0250 |